Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
[7] The company's primary products are tirzepatide (Mounjaro and Zepbound) for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea (56% of 2025 revenues)
For a detailed visual breakdown of these dose levels, see the tirzepatide dose chart and the compounded tirzepatide dosage chart
Operating income rose 13.1% to $2.06 billion, though net income stayed flat year over year
Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: a meta-analysis of clinical studies emphasising retinal changes as a primary outcome
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE
US$ 26.48
US$ 24.38
US$ 28.39
US$ 20.80
US$ 25.91
:format(jpg)/f.elconfidencial.com%2Foriginal%2Ff27%2Fb3a%2F460%2Ff27b3a460e92bcdc8635b6aa1b0eff12.jpg)
